Medicare Enrolled
Dr. David Lans, DO FACP
Rheumatology · New Rochelle, NY
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Lans from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Lans?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Lans
Dr. David Lans is a rheumatology specialist in New Rochelle, NY, with 21 years of NPI registration. Based on federal Medicare data, Dr. Lans performed 64,368 Medicare services across 895 unique beneficiaries.
Between the years covered by Open Payments, Dr. Lans received a total of $14,544 from 53 pharmaceutical and/or device companies across 838 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Lans is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 21 years in practice
▲ Top 7% volume in NY
$14,544 industry payments
Medicare Practice Summary
Medicare Utilization ↗64,368
Medicare services
Top 7% in NY for rheumatology
895
Unique beneficiaries
$11
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~3,065 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Certolizumab injection (Cimzia) An injection of certolizumab pegol administered under the direct supervision of a physician. |
39,400 | $4 | $14 |
| Golimumab infusion (Simponi Aria) Administration of golimumab medication directly into a vein. This code specifies the dosage amount of 1 milligram for intravenous delivery. |
13,250 | $11 | $50 |
| Abatacept infusion (Orencia) An injection of abatacept administered under the direct supervision of a physician. This code is used for Medicare when the drug is not self-administered. |
5,675 | $34 | $200 |
| Infliximab-abda biosimilar injection, 10 mg This code represents the administration of a 10 mg dose of infliximab-abda, a biosimilar medication. It covers the injection of this specific pharmaceutical product. |
2,240 | $28 | $297 |
| Denosumab injection (Prolia/Xgeva) | 1,920 | $19 | $30 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
286 | $75 | $371 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
257 | $70 | $150 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
240 | $27 | $400 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
217 | $104 | $400 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
168 | $126 | $400 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
161 | $62 | $300 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
147 | $8 | $15 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
72 | $49 | $250 |
| Methylprednisolone acetate injection, 80 mg An injection of 80 mg of methylprednisolone acetate, a corticosteroid medication. |
68 | $9 | $150 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
56 | $13 | $125 |
| Office visit for established patient An office visit for an existing patient that may not require the healthcare professional to be present. |
48 | $19 | $125 |
| Joint injection, major joint Removal of fluid from a large joint and/or injection of medication into the joint space. |
44 | $57 | $151 |
| Quadrivalent influenza vaccine, cell-culture derived A flu shot containing four strains of influenza virus, produced using cell culture technology rather than eggs. This formulation is free from preservatives and antibiotics. |
29 | $33 | $75 |
| Flu vaccine administration This procedure involves the administration of the influenza virus vaccine. It covers the process of delivering the vaccine to the patient. |
29 | $36 | $60 |
| Electrocardiogram (EKG), 12-lead A standard heart rhythm test using at least 12 leads to record electrical activity. A healthcare provider interprets the results and provides a written report. |
22 | $11 | $75 |
| New patient office visit, complex (60-74 min) | 20 | $196 | $735 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
19 | $134 | $450 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
29.9% high complexity
68.7% medium
1.4% routine
Industry Payment Transparency
Open Payments through 2024 ↗$14,544
Total received (2018-2024)
Avg $2,078/year across 7 years
Top 23% in NY for rheumatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
53
Companies
838
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$14,353 (98.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$192 (1.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,683
2023
$1,879
2022
$2,101
2021
$2,246
2020
$1,741
2019
$1,847
2018
$2,046
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$721
Amgen Inc.
$347
ABBVIE INC.
$346
PFIZER INC.
$177
Janssen Biotech, Inc.
$157
UCB, Inc.
$151
Lilly USA, LLC
$99
Antares Pharma, Inc.
$86
Mallinckrodt Hospital Products Inc.
$80
ANI Pharmaceuticals, Inc.
$79
Genentech USA, Inc.
$75
Novartis Pharmaceuticals Corporation
$67
Regeneron Healthcare Solutions, Inc.
$63
Organon Llc
$49
E.R. Squibb & Sons, L.L.C.
$45
GlaxoSmithKline, LLC.
$40
Exact Sciences Corporation
$23
IDORSIA PHARMACEUTICALS US INC
$21
Novo Nordisk Inc
$20
Aurinia Pharma U.S., Inc.
$20
Fidia Pharma USA Inc.
$17
Top 3 companies account for 52.7% of 2024 payments
All-time payments by company (2018-2024) ›
Amgen Inc.
$2,129
AstraZeneca Pharmaceuticals LP
$1,648
Janssen Biotech, Inc.
$1,385
ABBVIE INC.
$1,109
PFIZER INC.
$1,024
UCB, Inc.
$724
Lilly USA, LLC
$665
AbbVie, Inc.
$579
Novartis Pharmaceuticals Corporation
$553
GlaxoSmithKline, LLC.
$427
AbbVie Inc.
$386
Mallinckrodt Hospital Products Inc.
$368
E.R. Squibb & Sons, L.L.C.
$311
Regeneron Healthcare Solutions, Inc.
$283
Celgene Corporation
$267
Antares Pharma, Inc.
$248
Genentech USA, Inc.
$240
Genentech, Inc.
$192
Horizon Therapeutics plc
$166
ANI Pharmaceuticals, Inc.
$154
Organon LLC
$151
Novo Nordisk Inc
$122
Cumberland Pharmaceuticals, Inc.
$120
NOVARTIS PHARMACEUTICALS CORPORATION
$113
IDORSIA PHARMACEUTICALS US INC
$109
Merck Sharp & Dohme Corporation
$107
Flexion Therapeutics, Inc.
$91
Radius Health, Inc.
$88
Aurinia Pharma U.S., Inc.
$87
Alexion Pharmaceuticals, Inc.
$58
CSL Behring
$56
Janssen Pharmaceuticals, Inc
$54
Mallinckrodt Enterprises LLC
$51
Organon Llc
$49
Exeltis, USA Inc.
$37
Sobi, Inc
$34
Teva Pharmaceuticals USA, Inc.
$31
Amarin Pharma Inc.
$30
Fresenius Kabi USA, LLC
$28
DePuy Synthes Sales Inc.
$25
MEDEXUS PHARMA, INC.
$24
Merck Sharp & Dohme LLC
$24
Exact Sciences Corporation
$23
Impulse Dynamics (USA) Inc.
$22
Acella Pharmaceuticals, LLC
$20
Eisai Inc.
$20
Actelion Pharmaceuticals US, Inc.
$19
Baudax Bio Inc.
$18
West-Ward Pharmaceuticals
$18
Fidia Pharma USA Inc.
$17
Supernus Pharmaceuticals, Inc.
$16
Acerus Pharmaceuticals Corporation
$15
MEDAC PHARMA, INC.
$11
Top 3 companies account for 35.5% of all-time payments
Associated products mentioned in payments ›
ACTHAR · ANJESO · AVSOLA · Actemra · BENLYSTA · BREZTRI · Bimzelx · CHANTIX · COLOGUARD · COLOGUARD DNA CAPTURE REAGENTS · COSENTYX · Cimzia · Cologuard Collection Kit · DALIRESP · DUEXIS · DUPIXENT · Dayvigo · EVENITY · Enbrel · FARXIGA · FASENRA · HADLIMA · HUMIRA · HYMOVIS · Hizentra · Humira · ILARIS · INVOKANA · JARDIANCE · KEVZARA · KEVZARA SARILUMAB INJECTION · KRYSTEXXA · Kineret · LEQVIO · LUPKYNIS · LYRICA · MONOVISC · Mitigare · NOCDURNA · NP Thyroid 60 · Natesto · OCREVUS · OPSUMIT · ORENCIA · OTREXUP · Optimizer · Otezla · Otrexup · Ozempic · PREMARIN · PURIFIED CORTROPHIN GEL · QULIPTA · QUVIVIQ · RAYOS · REDITREX · REMICADE · RENFLEXIS · RINVOQ · Rasuvo · Rinvoq · Rituxan · Rybelsus · SAPHNELO · SIMPONI · SIMPONI ARIA · SKYRIZI · STELARA · STRENSIQ · SYMBICORT · Saxenda · Strensiq · TALTZ · TAVNEOS · TREMFYA · TRULICITY · Tavneos · Truxima · Tymlos · ULTOMIRIS · VERQUVO · Vascepa · XARELTO · XELJANZ · XOLAIR · XYOSTED · Zilretta
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (99%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Rheumatologists within 10 mi
371
Per 100K population
37.2
County median income
$118,411
Nearest hospital
MONTEFIORE MOUNT VERNON HOSPITAL
2.8 mi
2.8 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Lans is a mixed practice specialist, with above-average Medicare volume (top 7% in NY), with low-engagement industry engagement, with 21 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Lans experienced with certolizumab injection (cimzia)?
Based on Medicare claims data, Dr. Lans performed 39,400 certolizumab injection (cimzia) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Lans receive payments from pharmaceutical companies?
Yes. Dr. Lans received a total of $14,544 from 53 companies across 838 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Lans's costs compare to other rheumatologists in New Rochelle?
Dr. Lans's average Medicare payment per service is $11. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Lans) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Rheumatologists in New Rochelle
Browse rheumatologists in New Rochelle ranked by procedure volume and transparency data.
Highest volume
Top Rheumatologists in NY
Rheumatologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Rheumatologists in NY
Which NY rheumatologists receive the most from drug and device companies.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology